Today's Peptide News — September 9, 2026

Eli Lilly's triple agonist retatrutide, which activates the GIP, GLP-1, and glucagon receptors, produced an average body weight reduction of 28.3% at the highest 12 mg dose over 80 weeks in the Phase 3 TRIUMPH-1 study. The trial randomized 2,339 participants to retatrutide 4 mg, 9 mg, or 12 mg, or placebo, with doses titrated up every four weeks. Extended follow-up pushed average loss to roughly 30% at 104 weeks, and more than 45% of participants lost at least 30% of their body weight, a threshold usually associated with bariatric surgery.

The result matters because it is the largest weight-loss figure yet reported for a pharmacological agent in a Phase 3 obesity trial, and it validates the triple-agonist strategy as a genuine step beyond the dual agonism of tirzepatide. A regulatory filing is expected in late 2026, with approval unlikely before 2027 or 2028.

A short PeptideWiki post could frame retatrutide as "the peptide that adds glucagon" — explaining, in plain terms, how stacking a third receptor onto the GLP-1/GIP backbone drives both appetite suppression and energy expenditure, and why that mechanism appears to translate into surgery-level results.

A nationwide Swedish registry study led by Professor Mark Taylor of Griffith University analyzed 14,694 people with bipolar disorder prescribed diabetes medication between 2009 and 2024, of whom about 5,200 used a GLP-1 receptor agonist. Semaglutide use was associated with a 21% lower risk of psychiatric hospitalization, while liraglutide and dulaglutide showed no such association, hinting that the effect may be specific rather than a class-wide property. The work was published in Acta Psychiatrica Scandinavica.

The finding matters because it points to a possible neuropsychiatric benefit for a peptide already taken by millions, potentially through anti-inflammatory and brain-signaling pathways. The authors caution this is observational and does not establish that semaglutide prevents psychiatric episodes or treats bipolar disorder.

A PeptideWiki angle: use this as a hook for semaglutide's "beyond weight loss" story, walking through the emerging evidence that GLP-1 receptors in the brain may influence mood and cognition, while being clear about the limits of registry data.

A recent bioRxiv preprint describes a retro-inverso peptide, built from D-amino acids in reversed sequence to resist enzymatic degradation, that inhibits the formation of cross-alpha amyloid, triggers disassembly of pre-formed fibrils of a biofilm-forming modulin peptide, and disperses MRSA biofilm biomass in a dose-dependent manner. Targeting the structural scaffold of the biofilm rather than the bacteria directly is a mechanistically distinct approach to a notoriously drug-tolerant problem.

This matters because biofilms shield methicillin-resistant Staphylococcus aureus from antibiotics and immune clearance, and agents that dismantle the matrix could restore the effectiveness of existing drugs. As a preprint, the work is not yet peer reviewed.

A PeptideWiki post could explain retro-inverso design as a clever trick for making peptides stable in the body, then show how this candidate attacks the "glue" holding a biofilm together instead of trying to kill the bacteria outright.

A 2026 review in Cell and Tissue Research surveys the role of brain peptides in Alzheimer's disease pathophysiology and the therapeutic strategies now being built around them. It highlights advances in peptide chemistry that have enabled aggregation inhibitors, receptor-selective neuropeptide analogues, and cell-penetrating peptide conjugates targeting proteostasis, insulin signaling, and neurotrophic support. Companion reviews this year emphasize AI-guided design and the persistent challenge of blood-brain barrier delivery.

The finding matters because current Alzheimer's therapeutics offer largely symptomatic relief, and peptides can modulate the protein-protein interactions that small molecules struggle to reach. The bottleneck remains getting these molecules across the blood-brain barrier at meaningful doses.

A PeptideWiki angle: a primer on why peptides are attractive but hard to deploy against Alzheimer's, using the review to introduce concepts like cell-penetrating conjugates and aggregation inhibitors for a general audience.

Novo Nordisk has submitted a New Drug Application to the FDA for CagriSema, a once-weekly fixed-dose injectable that pairs the amylin analogue cagrilintide with semaglutide to hit two complementary obesity pathways. In the REDEFINE 1 Phase 3 trial, adults with obesity or overweight with a related complication lost an average of about 23% of body weight. A regulatory decision is expected in late 2026.

If approved, CagriSema would be the first fixed-dose amylin-GLP-1 combination, marking the arrival of amylin biology as a mainstream obesity target alongside the incretin pathway that has dominated the field.

The GLP-1 field is shifting from injectables toward pills. An oral formulation of semaglutide was cleared for weight management in late 2025, and in April 2026 the FDA approved orforglipron, the first oral small-molecule, non-peptide GLP-1 receptor agonist. Because it is not a peptide, orforglipron sidesteps the manufacturing and cold-chain constraints of peptide drugs and can be produced at scale far more cheaply.

The move to oral agents matters for access and adherence, and it sharpens a strategic question for the peptide field: how injectable peptide combinations and next-generation multi-agonists will compete against cheaper, more convenient small molecules.

Researchers reported a potential way to attack prostate cancers that escape treatment by changing their cellular identity, a process called lineage plasticity that lets tumors shed the features their therapies target. Combining two classes of drugs reversed many of these changes and sharply slowed tumor growth in preclinical experiments.

The work matters because treatment-resistant prostate cancer is a major driver of mortality, and targeting the identity switch itself, rather than a single receptor, could keep therapies working longer. The findings are preclinical and will need clinical validation.

An observational analysis found that starting statin therapy soon after a type 2 diabetes diagnosis was associated with a roughly 15% lower risk of developing dementia. The signal adds to a growing body of evidence connecting cardiovascular and metabolic management to long-term brain health.

The finding matters because diabetes is an established dementia risk factor and statins are cheap, widely used, and well tolerated. As an observational result, it shows association rather than proof of cause, and timing of treatment initiation may reflect other differences between patients.

Scientists discovered that combinations of toxin-blocking proteins naturally circulating in rattlesnake blood can potently neutralize venom from several dangerous snake species. The proteins appear to intercept and inactivate key venom toxins, suggesting a template for broad-spectrum antivenoms.

This matters because snakebite envenomation kills or disables hundreds of thousands of people each year, and current antivenoms are species-specific, costly, and prone to adverse reactions. A naturally evolved, broadly active neutralizing system could inform a new generation of treatments.

A large genomic study linked more than 1,200 genetic variants to the Big Five personality traits, and found that many of the same variants are also associated with health, longevity, career outcomes, income, and everyday habits. The overlap suggests personality and life outcomes share partly common biological roots.

The work matters for how researchers think about the interplay of genes, behavior, and wellbeing, though the effect of any single variant is tiny and personality remains strongly shaped by environment and experience.